Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00123643 · ClinicalTrials.gov registry record · Phase 4
Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
A Phase 4 study of Type 2 Diabetes Mellitus, sponsored by St. Paul Heart Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00123643 is a Phase 4 study of Type 2 Diabetes Mellitus that has completed, run by St. Paul Heart Clinic. The registered enrollment target is 36 participants, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00123643, a Phase 4 study of Type 2 Diabetes Mellitus, has completed, sponsored by St. Paul Heart Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the vascular effects of two commonly used diabetes medications, rosiglitazone and glyburide in type 2 diabetic patients.
Conditions Studied
Interventions
- DRUG rosiglitazone
- DRUG glyburide
Study Locations (1)
Minnesota
- St. Paul Heart Clinic - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2003-05 |
| Est. Completion | 2005-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00123643
The ClinicalTrials.gov registry entry for NCT00123643 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The listed sponsor is St. Paul Heart Clinic, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which rosiglitazone is the first listed.
NCT00123643 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00123643 about?
NCT00123643 is a clinical study titled "Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients". The purpose of this study is to compare the vascular effects of two commonly used diabetes medications, rosiglitazone and glyburide in type 2 diabetic patients.
What is the current status of trial NCT00123643?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2003-05. Estimated completion is 2005-12.
What conditions does trial NCT00123643 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT00123643?
The interventions under investigation include: rosiglitazone (DRUG), glyburide (DRUG).
Who is sponsoring clinical trial NCT00123643?
This trial is sponsored by St. Paul Heart Clinic, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00123643 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism
ACTIVE NOT RECRUITING · Phase 4
-
Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?
COMPLETED · Phase 4
-
Adding Liraglutide to High Dose Insulin: Breaking the Cycle
COMPLETED · Phase 4
-
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
COMPLETED · Phase 4
-
Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes
COMPLETED · Phase 4
-
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.